国泰海通证券股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为杭 州博拓生物科技股份有限公司（以下简称"博拓生物"或"公司"）首次公开发行 股票并在科创板上市的保荐机构，根据《上海证券交易所科创板股票上市规则》《上 市公司募集资金监管规则》《上海证券交易所科创板上市公司自律监管指引第1号— —规范运作》等法律法规和规范性文件的要求，对博拓生物使用部分暂时闲置募集资 金进行现金管理事项进行了审慎核查，核查情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于2021年7月27日 出具的《关于同意杭州博拓生物科技股份有限公司首次公开发行股票注册的批复》 （证监许可〔2021〕2497号），公司获准向社会公开发行人民币普通股2,666.6667 万股，每股发行价格为人民币34.55元，募集资金总额为92,133.33万元，扣除发行 费用9,196.41万元（不含增值税）后，募集资金净额为82,936.92万元。上述募集资 金到位情况已经中汇会计师事务所（特殊普通合伙）审验，并于2021年9月3日出具 了《 ...

格隆汇8月28日丨博拓生物(688767.SH)公布2025年半年度报告，报告期内，公司实现营业收入2.03亿 元，同比下降23.91%；归属于上市公司股东的净利润1240.24万元，同比下降82.82%；归属于上市公司 股东的扣除非经常性损益的净利润683.48万元，同比下降90.25%；基本每股收益0.07元。 ...

杭州博拓生物科技股份有限公司2025 年半年度报告 公司代码：688767 公司简称：博拓生物 杭州博拓生物科技股份有限公司 2025 年半年度报告 1 / 225 杭州博拓生物科技股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告"第三节 管理层讨论与分析"之"四、风险因素"中说明了可能对公司产生 重大不利影响的风险因素，敬请投资者注意投资风险。 √适用 □不适用 本报告所涉及的公司未来计划、经营计划、发展战略等前瞻性陈述，不构成公司对投资者的 实质承诺，请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人陈音龙、主管会计工作负责人俞苗苗及会计机构负责人（会计主管人员）俞苗 苗声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无。 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风 ...

博拓生物公告，2025年上半年营业收入2.03亿元，同比下降23.91%。净利润1240.24万元，同比下降 82.82%。 ...

Group 1 - The core point of the news is that 博拓生物's stock price has decreased by 5.01%, currently trading at 39.05 CNY per share, with a total market capitalization of 58.31 billion CNY [1] - 博拓生物, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 92.91% of its revenue coming from diagnostic reagent products [1] - The trading volume for 博拓生物 reached 2.27 billion CNY, with a turnover rate of 3.76% [1] Group 2 - From the perspective of major shareholders, 广发价值核心混合A (010377) holds 2.56% of 博拓生物's circulating shares, with a current floating loss of approximately 563.17 million CNY [2] - The fund has achieved a return of 68.54% year-to-date and 114.67% over the past year, ranking 147 out of 8194 and 129 out of 7963 respectively [2] - The fund manager, 吴远怡, has been in charge for 4 years and 333 days, with a total asset scale of 204.78 billion CNY [3] Group 3 - In the second quarter, 广发价值核心混合A (010377) held 423.6 million shares of 博拓生物, representing 2.75% of the fund's net value, making it the eighth largest holding [4] - The current floating loss for the fund regarding 博拓生物 is estimated at 872.62 million CNY [4]

Group 1 - On August 25, Botao Bio's stock increased by 0.15% with a trading volume of 201 million yuan [1] - The financing data shows that on the same day, Botao Bio had a financing purchase amount of 23.34 million yuan and a financing repayment of 26.15 million yuan, resulting in a net financing buy of -2.81 million yuan [1] - As of August 25, the total balance of margin trading for Botao Bio was 190 million yuan, which accounts for 3.11% of its circulating market value, indicating a high level compared to the past year [1] Group 2 - As of March 31, the number of shareholders for Botao Bio was 6,212, a decrease of 2.11% from the previous period [2] - For the first quarter of 2025, Botao Bio reported an operating income of 87.89 million yuan, a year-on-year decrease of 35.20%, and a net profit attributable to shareholders of 8.73 million yuan, down 77.97% year-on-year [2] - Since its A-share listing, Botao Bio has distributed a total of 798 million yuan in dividends, with 478 million yuan distributed over the past three years [2]

证券代码：688767 证券简称：博拓生物 公告编号：2025-036 杭州博拓生物科技股份有限公司 实际控制人减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持股的基本情况 截至本公告披露日，杭州博拓生物科技股份有限公司（以下简称"公司"） 实际控制人于秀萍女士持有公司股份 24,953,600 股，占公司股份总数的 16.71%。 上述股份均为公司首次公开发行前取得的股份、因权益分派转增的股份，均已上 市流通。 ? 减持计划的主要内容 因自身资金需求，于秀萍女士拟通过大宗交易或集中竞价方式减持合计不超 过 4,479,999 股，即不超过公司股份总数的 3%。其中：以集中竞价方式减持不 超过 1,493,333 股，不超过公司股份总数的 1%；以大宗交易方式减持不超过 股份。若在上述减持期间内，公司有送红股、转增股本、增发新股等股份变动事 项，对应的减持股份数量、价格将进行相应的调整。 一、减持主体的基本情况 股东名称 于秀萍 控股股东、实控人及一致行动人 √是 □ ...

Core Viewpoint - The actual controller of Botao Bio (688767.SH), Yu Xiuping, announced a share reduction plan due to personal funding needs, intending to reduce up to 4,479,999 shares, which is no more than 3% of the total shares [1][2]. Summary by Relevant Sections Share Reduction Plan - Yu Xiuping plans to reduce shares through block trading or centralized bidding, with a maximum of 1,493,333 shares (1% of total shares) via centralized bidding and 2,986,666 shares (2% of total shares) via block trading [1][2]. - The reduction period is set for three months starting from 15 trading days after the announcement [1][2]. Shareholding Information - As of the announcement date, Yu Xiuping holds 24,953,600 shares, accounting for 16.71% of the total shares [2]. - The shares intended for reduction were acquired before the IPO and through rights distribution [2]. Financial Performance - Botao Bio's initial public offering raised a total of 921 million yuan, with a net amount of 829 million yuan after expenses, which were 91.96 million yuan [3]. - The net profits attributable to shareholders from 2021 to 2024 were 834 million yuan, 774 million yuan, 107 million yuan, and 170 million yuan, respectively [3].

Core Viewpoint - A total of 22 A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1] Group 1: Companies and Their Reduction Plans - Dongfang Ocean plans to reduce its holdings by no more than 3% [2] - Nanmin Group's two shareholders intend to reduce their holdings by no more than 3.63% [2] - Xinhai Optoelectronics' shareholders Gao Zhan and Zhou Xuan plan to reduce their shares [2] - Yiming Food's shareholders will collectively reduce their holdings by no more than 3% [2] - Yingshi Sheng's shareholders plan to reduce their holdings by no more than 2% [2] - Jereh's vice chairman Wang Jili plans to reduce no more than 723,000 shares [2] - Hengyu Xintong's shareholders intend to reduce their holdings by no more than 2% [2] - Ruoyuchen's shareholder Langjing's shareholding will drop below 2% [2] - Zhongchumei's shareholder Wang Jing plans to reduce no more than 1% [2] - Jiangbolong's five employee shareholding platforms plan to reduce no more than 1.31% [2] - Puyuan Information's actual controller and its concerted actors plan to reduce their holdings by no more than 2.9951% [2] - Botuo Biological's actual controller Yu Xiuping plans to reduce no more than 3% [2] - Sanbo Brain Science's shareholder TBP plans to reduce no more than 3% [2] - Yijiahe's Huatai Zhanxin Investment and Daofeng Investment plan to reduce no more than 2% [2] - Rongzhirixin's controlling shareholder and concerted parties plan to reduce no more than 3% [2] - Taijin Investment's shareholders plan to reduce no more than 3% [2] - Xidian New Energy's shareholder Changjiang Chen Dao plans to reduce no more than 2% [2] - Huoshan's two shareholders plan to reduce a total of 5.45% [2] - Dongfang Zhaoye's chairman Feng Liming plans to reduce no more than 131,500 shares [2] - Nanjing New Hundred plans to reduce no more than 6 million shares of repurchased stock [2] - Xagong's shareholder Xiamen Kouhang plans to reduce no more than 1% [2] - Jinhongshun's shareholder Gaode Investment plans to reduce no more than 3% [2]

Shareholder Reduction - Shareholders Gao Zhan and Zhou Xuan of Xinhau Optoelectronics plan to reduce their holdings by a total of no more than 1.0176 million shares [1] - Shareholders Xinyue Investment, Mingniu Investment, and Chengyue Investment of Yiming Food plan to reduce their holdings by a total of no more than 12.03 million shares [1] - The consistent action party of shareholders holding more than 5% of Yingshisheng plans to reduce their holdings by no more than 2% [1] - Chairman and General Manager Nie Weihua of Rongzhi Rixin plans to reduce his holdings by no more than 1.40% [1] - Major shareholder Wang Jing of Zhongchumei plans to reduce his holdings by no more than 1.76 million shares [1] - Shareholder Huatai Zhanzheng Investment of Yijiahe plans to reduce their holdings by no more than 4.0972 million shares [1] - Actual controller Yu Xiuping of Botuo Biological plans to reduce his holdings by no more than 3% [1] Other Financial Information - Electric Science Cybersecurity reported a net loss of 170 million yuan in the first half of the year [1] - Ziaotai reported a net loss of 125 million yuan in the first half of the year [1]